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AbstrACt
Objectives To estimate trends in HIV testing, positivity and 
prevalence in UK primary care for 2000–2015 as part of a 
wider investigation into reasons for late diagnosis of HIV.
Design Retrospective cohort study using the Clinical 
Practice Research Datalink (CPRD) which is derived from 
computerised clinical records produced during consultations 
in primary care.
setting 404 general practices in England.
Participants 5 979 598 adults aged ≥16 years registered 
between 2000 and 2015 with 45 093 761 person years of 
observation.
Outcomes Annual HIV testing rates, proportion of positive 
tests and prevalence of HIV- infected people recorded in 
primary care 2000–2015.
results HIV testing in primary care increased from 2000 to 
2010, but then declined. Testing was higher in females than 
in males and in those aged 16–44 years compared with older 
adults. Rates per 100 000 in women aged 16–44 years were 
177 (95% CI 167 to 188); 1309 (95% CI 1282 to 1336); 1789 
(95% CI 1757 to 1821) and 839 (95% CI 817 to 862) in 2000, 
2005, 2010 and 2015, respectively, and for non- pregnant 
women: 22.5 (95% CI 19 to 26); 134 (95% CI 125 to 143); 
262 (95% CI 250 to 275); 190 (95% CI 179 to 201). For men 
aged 16–44 years rates were: 26 (95% CI 22 to 29); 107 
(95% CI 100 to 115); 196 (95% CI 185 to 206); 137 (95% CI 
127 to 146). Over the study period, there were approximately 
two positive results per 1000 HIV tests. Men were eightfold 
more likely to test positive than women. The percentage of 
HIV diagnoses among adults recorded in CPRD may be as 
low as 55% in London and 67% in the rest of the UK.
Conclusions HIV testing rates in primary care peaked in 
2010 and subsequently declined. Access to testing was 
higher for women despite the prevalence of HIV being higher 
in men.
Implications and further research needed Opportunities 
remain in primary care for increasing HIV testing to prevent 
costly late diagnoses and decrease HIV transmission. 
Interventions to improve targeting of tests and increase 
adherence to HIV testing guidelines are needed in primary 
care.
IntrODuCtIOn
HIV testing in primary care is an important 
component of the strategy to diagnose HIV 
earlier and reduce transmission of HIV. In 
2015 there were an estimated 89 800 (95% 
credible interval (CrI) 87 100 to 94 800) 
people living with HIV in England of whom 
approximately 15% (CrI 12%–19%) were 
unaware of their infection.1 Of those indi-
viduals newly diagnosed with HIV in 2015, 
39% were diagnosed late, defined as having 
a CD4 count below 350 cells/mL within 3 
months of diagnosis.2 An estimated 1 in 4 
of newly diagnosed individuals experienced 
a missed opportunity for an earlier diag-
nosis within the healthcare system in the 
preceding year.3 Late diagnosis of HIV is 
associated with increased hospitalisations, 
decreased life expectancy4–7 and higher 
treatment and care costs to the National 
Health Service (NHS).8 Importantly, indi-
viduals with undiagnosed HIV are likely to 
strengths and limitations of this study
 ► We investigated trends in HIV testing in primary care 
using high quality data from the Clinical Practice 
Research Datalink (CPRD) which is derived from 
computerised clinical records produced during con-
sultations in primary care in England.
 ► CPRD provided anonymised primary care records on 
patients registered between 2000 and 2015 in 404 
primary care practices in England which is likely to 
be representative of the general patient population.
 ► A limitation of the study is that not all general prac-
tices contribute data to CPRD and therefore we can-
not know whether the sample was representative.
 ► A major strength of the study was the large num-
ber of patients, nearly 6 million, which allowed us to 
contrast trends in HIV testing rates in primary care 
by sex, age, deprivation, rural/urban location and 
whether in London or not.
 ► Data were available for 15 years of follow- up al-
lowing us to show that HIV testing in primary care 
in England increased between 2000 and 2010, but 
then declined up to 2015.
Protected by copyright.
 o
n
 N
ovem
ber 27, 2019 at University of Bristol Library.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-027744 on 24 November 2019. Downloaded from 
2 Gompels M, et al. BMJ Open 2019;9:e027744. doi:10.1136/bmjopen-2018-027744
Open access 
be responsible for the majority of transmissions because 
successfully treated individuals are unlikely to infect 
others.9
Enhanced HIV testing is considered to be cost- effective in 
areas with a local diagnosed HIV prevalence that exceeds 2 
per 1000 in adults aged 15–59 years.2 10 In these high HIV 
prevalence areas recommendations are an HIV test should 
be routinely offered to all new general practitioner (GP) 
registrations, those undergoing tests for other sexually 
transmitted infections or having blood tests for any reason, 
and all new hospital medical admissions.2 11 However, the 
majority of people with HIV seek medical care for a related 
condition several times prior to their HIV diagnosis.12 13 This 
may be presenting to general practice or hospital care. But 
without a high degree of clinical suspicion, the diagnosis 
is often missed.14 The British HIV Association(BHIVA) 
has published a list of indicator diseases that are more 
commonly found in those who are HIV positive than nega-
tive.15 HIV testing is recommended in these cases, but recent 
surveys suggest poor adherence to guidelines.16 17 Given the 
increase in HIV prevalence over time we would expect that 
there would be an increase in GP testing for HIV.
Evidence from systematic reviews shows that there are 
often many barriers to testing experienced by patients and 
equally by healthcare professionals (HCP).18–20 Patients 
presenting with clinical indicator conditions to their GP 
provide a valuable opportunity to diagnose HIV and avoid 
hospitalisations due to late diagnosis.21 Research has shown 
that the majority of patients (up to 75%) newly diagnosed 
with HIV had been seen in the healthcare system within 
the 12 months prior to their diagnosis resulting in a missed 
opportunity to test.12 14 22 23Opt out HIV testing has been 
shown to be feasible, acceptable and cost effective in 
eight pilot studies conducted in community, primary and 
secondary care settings in high prevalence areas across 
England.24 However, no recent evidence is available to 
know if HIV testing in primary care has been increasing and 
guidelines have been implemented over the country and 
not just in high risk areas.16 17
HIV testing in primary care has been reported only for 
the years 1995–2005 using data from the UK General Prac-
tice Research Database (GPRD).25 This study showed that 
testing in primary care remained low, but increased steadily. 
Our main objective was to analyse data from the same 
source collected between the years 2000 and 2015 to study 
if HIV testing trends continued to increase in primary care 
over this extended time period. In addition we investigated 
differences in HIV testing rates and HIV diagnosis by demo-
graphic characteristics and estimated the prevalence of HIV 
recorded in primary care and compared it with estimates 
from national surveillance.
MethODs
 Population and data
We used data from the Clinical Practice Research Data-
link (CPRD), previously known as the GPRD, which is 
derived from computerised clinical records produced 
during consultations in primary care. The CPRD data-
base contains information from GP practices in the UK 
using the Vision software system (roughly 9% of UK 
practices) who consent to data collection; the sample is 
broadly representative of the adult UK population.26 Only 
GP practices in England are eligible for linkage to other 
data sets such as hospital admissions and practices can 
opt out of linkage. CPRD provided anonymised primary 
care records and linked secondary care and mortality 
records on patients registered between 2000 and 2015 in 
404 primary care practices in England. Data were avail-
able on nearly 6 million people aged over 16 years old. 
GPs enter data on tests, diagnoses and symptoms using 
Read codes that are a hierarchical alphanumeric system 
similar to, but more extensive than International Classi-
fication of Disease (ICD) codes. The list of Read codes 
used to identify (1) HIV tests25 (2) HIV diagnoses25 (3) 
pregnancy/delivery/abortion27 and (4) additional CPRD 
browser pregnancy medcodes is listed as appendices 1 to 
4, respectively, in the online supplementary file. We used 
individual level quintiles of the Index of Multiple Depri-
vation (IMD), 2015.28 Practices were classified as rural, 
urban conurbation or city/town at lower super output 
level (a small area geographic boundary of around 1500 
people) in England based on Office for National Statistics 
classifications, 2011,29 and as within or outside London. 
Ethnicity was grouped as Asian, Black African, Black 
Caribbean, Other, White and unknown based on linked 
Hospital Episode Statistics data.
We used national surveillance data from Public Health 
England (PHE) on testing in primary care derived from 
general practices that submit HIV tests to laboratories 
participating in the Sentinel Surveillance of Blood Borne 
Virus Testing (SSBBV). These practices cover 35% of 
England’s primary care population. HIV testing data are 
captured from 66% of the primary care population in 
extremely high prevalence areas (>5/1000), 37% within 
high prevalence areas (>2/1000) and 29% within low 
prevalence areas. These data exclude any point of care 
tests carried out by GPs, and tests carried out as part of 
antenatal screening. The latest data available on testing 
rates and positivity were for 2015.30 Data on HIV preva-
lence were derived from the HIV and AIDS Reporting 
System (HARS) and for earlier years the Survey of Preva-
lent HIV Infections Diagnosed (SOPHID) available from 
PHE.2 These data were available up to 2015.
Patient and public involvement
Public and patients were not involved in the design of this 
study. Patient data from general practices were contrib-
uted via CPRD and PHE surveillance as stated earlier.
 statistical methods
 HIV testing rate, positivity and prevalence of HIV recorded in 
primary care
Using data from CPRD we estimated the HIV testing 
rates for each year between 2000 and 2015, overall and 
by patient demographics. Testing rates were estimated 
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Table 1 Patient and practice demographics
Demographic
variable Group Frequency Percentage (%)
Gender
  
  
Males 2 871 884 48.03
Females 3 107 562 51.97
Other/unknown 152 0.00
Age (in 2015)
  
16–44 2 684 443 44.89
>44 3 295 155 55.11
Ethnicity
  
  
  
  
  
Asian 147 295 2.46
Black African 45 632 0.76
Black 
Caribbean
28 558 0.48
Other 118 934 1.99
White 3 328 189 55.66
Unknown 2 310 990 38.65
Region
  
  
Outside London 4 693 116 78.49
London 1 129 924 18.90
Unknown 156 558 2.62
Urban/rural
  
  
  
Urban 
(conurbation)
2 134 497 35.70
Urban (city/
town)
2 991 079 50.02
Rural 697 452 11.66
Unknown 156 558 2.62
Patient IMD 
(2015) 1=least 
deprived, …, 
5=most deprived
Quintile 1 1 285 213 21.49
Quintiles 2,3,4 3 564 936 59.62
Quintile 5 964 853 16.14
Unknown 164 596 2.75
Practice IMD 
(2015) 1=least 
deprived, …, 
5=most deprived
Quintile 1 1 249 293 20.89
Quintiles 2,3,4 3 702 313 61.92
Quintile 5 871 434 14.57
Unknown 156 558 2.62
IMD, Index of Multiple Deprivation.
for males and females, for all ages and grouped by age 
(16–44,≥45 years, chosen to match the study by Evans 
et al25). We also estimated rates separately according to 
whether the practice was in London or not, and by type of 
location. For each calendar year, the denominator used to 
calculate the HIV testing rate was the number of patients 
who were in the CPRD cohort in that year satisfying the 
following inclusion criteria:
1. They were registered before 30 June of that year.
2. They did not transfer to another practice or die before 
30 June of that year.
3. They were in the same practice for at least 6 months.
4. They had not previously tested positive for HIV.
The numerator was the number of HIV tests carried out 
within the relevant year. For each patient in the denom-
inator, the number of tests was calculated, disregarding 
repeat tests that were within a 3- month period. Any test 
done or registered more than 90 days after the first 
recorded positive test was ignored.
As the majority of HIV tests in women are carried out 
as part of antenatal screening, analyses for females were 
repeated excluding these tests. We identified women who 
were pregnant using either delivery dates or Read codes 
as follows:
1. Delivery (birth) dates associated with the females in 
our data: An HIV test was considered antenatal if it oc-
curred between 3 and 9 months before the recorded 
delivery date.
2. Read codes indicating any sign of pregnancy (antena-
tal): In this case an HIV test was considered antenatal 
if it occurred within 6 months from the day the Read 
code was recorded.
3. Read codes associated with the postpartum period: In 
this case the HIV test was considered antenatal if it oc-
curred within 3–10 months before the corresponding 
record.
4. Read codes indicating any sign of miscarriage or abor-
tion: An HIV test was recorded as antenatal if it oc-
curred between 3 months prior to 3 months after the 
corresponding record.
The Read codes associated with pregnancy are listed in 
the online supplementary material. The antenatal HIV 
tests were excluded from the numerator and the corre-
sponding patients were removed from the denominator 
for the related period as well.
We plotted the trends in HIV testing rates per 100 
000 person years for 2000–2015 separately for men and 
women (including and excluding antenatal HIV tests) 
for all adults and restricted to those aged 16–44 years 
old. In addition, we calculated the annual proportion of 
HIV tests that were positive for each year to investigate 
whether testing improved in terms of targeting higher 
risk individuals during the later years.
For the years 2005, 2010 and 2015, we estimated and 
tabulated HIV testing rates and incidence rate ratios 
(IRRs) with 95% CI from Poisson models for males and 
females separately according to whether practice was in 
London or not, by age, ethnicity, IMD and by type of 
location. To validate our estimates of HIV testing rates 
recorded in CPRD, we compared them with those from 
national surveillance data collected by PHE for 2015.30 
Finally, we estimated the prevalence of diagnosed HIV 
recorded in CPRD and compared this with estimated 
prevalence from national surveillance data collected by 
PHE using SOPHID and HARS to determine the propor-
tion of all HIV diagnoses that were recorded in CPRD . 
Data analysis was performed using STATA V.14.
results
Data were available on 5 979 598 distinct patients with 45 
093 761 (males 22,155,768; females 22,937,630) person 
years of observation. The demographic characteristics of 
included individuals are shown in table 1. There were less 
males (48%) than females (52%). Practices (15%) and 
individuals (16%) in the most deprived quintile of IMD 
were under- represented in CPRD. The total number of 
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Figure 1 Trend in HIV testing rates per 100 000 person years for the period 2000–2015 by gender and age group, with and 
without inclusion of antenatal testing.
Figure 2 Trend in the percentage of HIV tests that were 
positive for the period 2000–2015 by gender and age group, 
with and without inclusion of antenatal testing.
HIV tests recorded in CPRD between 2000 and 2015 was 
159 115 of which 357 (0.2%) were positive.
 trends in hIV testing rates 2000–2015 in primary care
Figure 1 shows the trend in HIV testing rates per 100 000 
person years for the period 2000–2015 by gender and age 
group, with and without inclusion of antenatal testing. 
The main reason for HIV testing among women of child-
bearing age was antenatal screening: the testing rates (per 
100 000 person- years) in all women aged 16–44 increased 
from 177 (95% CI 167 to 188) in 2000 to 1789 (95% CI 
1757 to 1821) in 2010 and then decreased to 839 (95% CI 
817 to 862) in 2015, with the corresponding figures being 
23 (95% CI 19 to 26), 262 (95% CI 250 to 275) and 190 
(95% CI 179 to 201) when antenatal testing was excluded. 
For males the corresponding rates were 26 (95% CI 22 to 
29), 196 (95% CI 185 to 206) and 137 (95% CI 127 to 146), 
which are lower than rates for females even when ante-
natal tests are excluded. HIV testing rates in primary care 
peaked in females in 2010 (figure 1) and have declined 
markedly since then. In men and women not tested ante-
natally, HIV testing rates increased until 2012–2013, but 
have declined since. Similar patterns were seen when data 
were restricted to those aged 16–44 years only, except that 
rates were much higher in younger adults compared with 
those aged 45 years and over (online supplementary table 
1 all adults, online supplementary table 2 for those aged 
16–44 years).
 trends in positive hIV diagnosis in primary care
Although the number of HIV tests was much higher in 
women, more men tested positive: 196/20,328 (0.96%) 
men compared with 161/138,787 (0.12%) women. This 
was skewed by a very low rate of positive diagnoses in 
younger females who were screened antenatally. The 
smoothed trend in the percentage of tests that were 
positive for men and women of different ages is shown 
in figure 2 (plot of raw data is shown in online supple-
mentary figure). Percentage positive (excluding ante-
natal tests) was similar in men and women before 2005, 
but declined more sharply in women thereafter. The 
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percentage of tests that were positive peaked around 2003 
and has fallen sharply since 2010, indicating that there is 
no evidence of better targeting of testing to individuals in 
later years.
 hIV testing rates in practices within and outside london, by 
age and deprivation index
HIV testing rates were twofold higher in London compared 
with outside London for both men and women in 2005 
and this differential increased in 2010 and 2015. Tables 2 
and 3 give the testing rates for years 2005, 2010 and 2015 
for males and females (excluding antenatal tests), respec-
tively, stratified by whether the practices were in London 
or outside London. Data for all years between 2000 and 
2015 are given for all adults (online supplementary table 
1) and for adults aged 16–44 years (online supplementary 
table 2). In more recent years practices outside London 
but in conurbations had higher rates than those in cities 
or towns, which, in turn, had higher rates than rural prac-
tices. Although testing rates in men in London practices 
decreased between 2010 and 2015 overall from 273 (95% 
CI 251 to 295) to 246 (95% CI 225 to 266) per 100 000 
person- years, there was evidence of a shift in targeting 
of testing since rates increased in older men from 151 
(95% CI 127 to 176) to 180 (95% CI 154 to 206) per 
100 000 person years and in the most deprived quintile 
from 415 (95% CI 351 to 480) to 565 (95% CI 487 to 
643) per 100 000 person years. This targeting effect was 
also seen among women in London practices, but not in 
practices outside London. However, in 2015 in London 
it remained the case that older people were less likely to 
be tested: IRR for age ≥45 compared with 16–44 years was 
0.59 (95% CI 0.50 to 0.71) for men and 0.46 (95% CI 0.38 
to 0.55) in women. The corresponding IRRs for outside 
London were much lower: IRR for age ≥45 compared 
with 16–44 years was 0.37 (95% CI 0.32 to 0.43) in men 
and 0.18 (95% CI 0.16 to 0.21) in women. In contrast, by 
2015 the most deprived group were two/threefold more 
likely to be tested than the least deprived, depending on 
gender and locality, with IRR for IMD quintile 5 versus 1 
increasing markedly from 2005 to 2015 (table 2 (males) 
and table 3 (females)).
 hIV testing rates and positivity according to national 
surveillance data
For comparison, national surveillance data for 2015 esti-
mated that general practices in extremely high preva-
lence areas (defined as greater than 5/1000 population, 
comparable with ‘London’ in our CPRD study) carried 
out the highest number of tests per practice population 
860 per 100 000 person years. This was nearly double 
the coverage rate of general practices in high diagnosed 
prevalence areas (defined as greater than 2/1000 popu-
lation), which was estimated at 440 per 100 000 person 
years, and ten times the coverage rate among general 
practices in low diagnosed prevalence areas, which was 
estimated at 90 per 100 000 person years. The estimates of 
HIV testing rates from surveillance were higher than our 
estimates from CPRD (tables 2 and 3). The proportion 
of positive tests among those tested in primary care esti-
mated from SSBBV surveillance data was 0.4% in 2015.30 
This varied from 0.5% in very high prevalence areas to 
0.2% in low prevalence areas and was consistent with our 
estimated positivity (figure 2).
 Prevalence of recorded hIV in CPrD and comparison with 
national surveillance estimates
In 2015 the prevalence of diagnosed HIV recorded in 
CPRD was 2.8 per 1000 adult patients in London practices 
and 0.8 per 1000 in the rest of the UK (table 4). According 
to PHE surveillance, in 2015 HIV prevalence in UK was 
estimated to be 1.6 per 1000, and excluding undiagnosed 
HIV was 1.3 per 1000 population.2 The HIV prevalence 
in London was estimated to be 4.7 per 1000, substantially 
higher than the rest of the UK at 1.1 per 1000. The corre-
sponding observed prevalence, that is, excluding undiag-
nosed cases of HIV, was 4.2 and 0.9 per 1000 population 
in London and the rest of the UK, respectively.2 However, 
these percentages are likely to be overestimated as chil-
dren aged <16 years were not included in the CPRD calcu-
lations of prevalence but were included in PHE data. In 
general practices in London, prevalence of HIV recorded 
in CPRD was higher for males, older individuals, Black 
African ethnicity and most deprived quintile (table 4) 
with a similar pattern in practices outside London except 
that prevalence did not vary by age.
DIsCussIOn
 statement of principal findings
Our analysis of CPRD data on GP consultations recorded 
on approximately 6 million people living in the UK over 
a 15- year period shows that the initial rise in HIV testing 
seen in primary care between 2000 and 2010 reversed 
with a significant drop in the testing rates for HIV in 
primary care from 2010. This is an unexpected finding 
as throughout this period prevalence of HIV has been 
increasing which should have engendered higher rates 
of testing in primary care, given the NICE recommen-
dations on testing, which would increase with increased 
prevalence.31 32 HIV testing rates in primary care were 
higher in women than men throughout the study period, 
even when tests for antenatal screening were excluded, 
despite HIV prevalence being higher in men. This 
resulted in men being eightfold more likely to test posi-
tive than women in this setting. Over the 15- year period 
of the study, there were approximately two positive results 
per 1000 HIV tests. We did not find evidence of better 
targeting of HIV testing to individuals in more recent 
years as the percentage of tests that were positive peaked 
around 2003. Many individuals at high risk of HIV infec-
tion may choose to test in settings other than general 
practice, such as sexual health clinics, which might make 
it harder to target HIV testing among the population 
attending primary care.
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Table 4 Prevalence (with 95% CI) of diagnosed HIV recorded in CPRD (per 100 000 persons) by gender, age, ethnicity and 
patient IMD, for London and outside London
Prevalence (95% CI)
2005 2010 2015
London
  All 140 (129 to 151) 230 (216 to 244) 282 (267 to 297)
  Gender
   Males 191 (172 to 209) 294 (271 to 317) 369 (344 to 395)
   Females 91 (78 to 103) 170 (153 to 187) 199 (181 to 217
  Age
   16–44 168 (152 to 184) 234 (215 to 253) 229 (210 to 249)
   >44 103 (88 to 117) 226 (205 to 247) 341 (316 to 365)
  Ethnicity
   White 127 (112 to 143) 183 (164 to 202) 224 (202 to 246)
   Asian 45 (17 to 72) 84 (50 to 119) 96 (60 to 131)
   Black African 1465 (1205 to 1726) 2350 (2055 to 2646) 2597 (2294 to 2899)
   Black Caribbean 195 (97 to 294) 431 (291 to 572) 538 (381 to 695)
  Patient IMD (2015)
   Quantile 1 32 (19 to 45) 86 (65 to 107) 121 (96 to 146)
   Quantiles 2,3,4 136 (122 to 149) 212 (195 to 228) 256 (238 to 274)
   Quantile 5 268 (230 to 306) 444 (397 to 491) 544 (492 to 596)
Outside London
  All 38 (36 to 41) 64 (61 to 67) 81 (77 to 85)
  Gender
   Males 50 (46 to 54) 81 (76 to 86) 105 (99 to 110)
   Females 26 (23 to 29) 48 (44 to 52) 58 (54 to 62)
  Age
   16–44 55 (51 to 59) 78 (72 to 83) 82 (76 to 87)
   >44 22 (19 to 25) 52 (48 to 56) 80 (76 to 85)
  Ethnicity
   White 29 (26 to 32) 46 (43 to 50) 60 (56 to 64)
   Asian 37 (16 to 59) 40 (21 to 59) 55 (34 to 76)
   Black African 2537 (2110 to 2964) 3663 (3236 to 4091) 3933 (3514 to 4353)
   Black Caribbean 135 (35 to 236) 347 (195 to 499) 484 (308 to 660)
  Patient IMD (2015)
   Quantile 1 19 (16 to 23) 31 (26 to 35) 42.58 (37 to 48)
   Quantiles 2,3,4 35 (32 to 38) 60 (56 to 65) 77 (72 to 81)
   Quantile 5 82 (72 to 91) 132 (121 to 144) 159 (146 to 172)
IMD, Index of Multiple Deprivation.
The pattern of HIV testing has also changed over time. 
Testing was twofold higher in London than elsewhere and 
has increased in the groups and areas of high deprivation 
within London. This is reassuring as it also reflects the 
higher prevalence of HIV in these areas and indicates that 
HIV testing has become more geographically targeted. 
Overall, testing rates were higher in urban conurbations 
and cities than in rural areas reflecting the national prev-
alence figures.2 Younger people were more likely to be 
tested than those aged 45 years and over, which reflects 
the incidence pattern for HIV. However, our data show 
an increasing trend in the rate of testing among the older 
age group in London, but not elsewhere, which may have 
been driven by the recognition that among those with 
HIV infection the proportion diagnosed late is higher in 
older age groups.33
In 2015, the prevalence of HIV recorded in CPRD was 
over threefold higher in London than elsewhere, but 
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overall was substantially lower than the prevalence of 
diagnosed HIV estimated from PHE surveillance.2 This 
may be due to HIV- positive individuals not using primary 
care or to non- disclosure of their HIV status to their GP, 
not recording of the diagnosis on GP systems, or to CPRD 
not including sufficient practices with high HIV preva-
lence. CPRD is broadly representative of primary care in 
the UK, but the UK HIV epidemic is concentrated in cities 
with approximately half of HIV- positive individuals living 
in London.2 The estimated percentage of HIV diagnoses 
among adults that were recorded in CPRD increased 
between 2005 and 2015 but was still substantially lower 
in London than elsewhere. This trend may reflect the 
ageing HIV population’s greater requirement of primary 
care services, decrease in stigma of disclosure, or better 
transfer and recording in primary care of positive results 
of HIV tests carried out in other settings in later years.
 strengths and weaknesses of the study
This study is very large with data from nearly six million 
patients followed over 15 years with detailed primary care 
records. This detailed coverage enabled us to accurately 
measure HIV testing rates according to the important 
factors of deprivation, urbanisation, gender, ethnicity and 
age. Records were collected prospectively and electron-
ically over a significant time period; therefore, we were 
able to show clearly the trends that have occurred. Our 
analysis and the data collection may be biased by several 
factors. The CPRD only includes a sample of general prac-
tices, but this is broadly representative of primary care 
in the UK, and, given the large numbers, this is a suffi-
cient sample size for estimates of testing rates to be accu-
rate. We have shown the CPRD slightly under- represents 
deprivation, in both individuals and GP practices. While 
this may be the case, given the very large sample size, we 
think that we can still draw valuable conclusions from 
this data. This study can only show the composite rates 
of testing in primary care. We were not able to categorise 
the different indications for an HIV test. What is clear, 
given the number of HIV positive patients, is that many 
patients will have been diagnosed in other healthcare 
settings, for example, PHE estimated that in England 
during 2016 5.9% and 7.3% of new diagnoses in men and 
women, respectively, were made in primary care.34 This 
implies that estimates of the prevalence of diagnosed 
HIV based on diagnoses recorded in CPRD will be under- 
estimates for the UK which we have shown by comparing 
with surveillance data from PHE.
 strengths and weaknesses in relation to other studies, 
discussing important differences in results
HIV testing in primary care in the Netherlands also 
decreased between 2010 and 2015 despite similar guide-
lines encouraging more pro- active screening for HIV.35 
Although HIV testing in primary care has declined, the 
rates of late diagnosis (CD4 count less than 350 cells/mL) 
have also declined from 50% in 2010 to 39% in 2015,36 
indicating a discordancy between the testing in primary 
care and diagnosis. This indicates that increased testing 
has likely occurred in other settings. Earlier diagnosis 
may be due to better detection in secondary care, either 
from screening or testing those with indicator conditions, 
or through other routes such as sexual health clinics, 
insurance requests or specialist testing services. More-
over, if testing has become better targeted in primary care 
and incidence in the consulting population is decreasing 
then even without an increase in testing, those who get 
tested may be tested earlier in the course of HIV infection 
leading to reduced rates of late diagnoses. However, we 
have shown a significant decline in HIV testing in primary 
care since the previous analysis by Evans et al25 on testing 
up to 2005, and therefore we can look at increased testing 
in primary care as an option to improve early HIV detec-
tion rates.
 Meaning of the study: possible explanations and implications 
for clinicians and policymakers
Since 2015, UK and international treatment guidelines37 
for those diagnosed with HIV recommend immediate 
treatment with antiretroviral therapy due to findings 
from the START trial.38 This change, together with pre- 
exposure prophylaxis, has resulted in a decline in HIV 
infection rates for the last 2 years34. Nevertheless, there 
are still opportunities for diagnosing HIV earlier in 
primary care while testing rates remain very low. Current 
UK testing guidelines34 recommend people attending 
general practices in areas of high HIV prevalence should 
be offered an HIV test at registration or when having a 
blood test if they have not had an HIV test in the past 12 
months. People newly diagnosed with an HIV indicator 
condition should also be offered an HIV test. The aim is 
to diagnose HIV earlier as late diagnosis of HIV is associ-
ated with increased morbidity and mortality.7 39 40 There 
are benefits for diagnosing HIV earlier both for the indi-
vidual in terms of quality of life and life expectancy6 and a 
wider societal benefit of reduced transmission and lower 
NHS treatment costs.
 unanswered questions and future research
Although it is a public health imperative, and target, 
to increase HIV testing and diagnosis, it is unclear how 
this could be implemented in primary care. A literature 
review undertaken of public and HCP attitudes towards 
HIV testing in the UK showed that a proactive offer of an 
HIV test by the HCP was an important factor which could 
help increase testing rates.20 Reasons for low levels of HIV 
testing by the HCP include fear/concern of offending 
patients, inadequate knowledge/training on HIV, low 
awareness of current testing guidelines, underestima-
tion of patient risk, insufficient time, competing priori-
ties, perceived burdensome consent process and pre- test 
discussion.18–20 41 Studies indicate a need for education 
and training on HIV testing for HCP in primary care to 
overcome these barriers to testing.16 42 Adequate interven-
tions are needed to address these barriers so individuals 
can receive a timely HIV test and with it the important 
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treatment benefits and care if found to be HIV positive. 
Another literature review has provided evidence that HIV 
indicator conditions have the potential to be used more 
effectively as triggers for earlier HIV testing.43 Opt- out 
testing can facilitate increased HIV testing as has been 
evident from a trial in emergency care setting.44 When 
blood tests are carried out for any reason in primary 
care, there could also be an opt- out HIV test. Computer 
prompts based on risk algorithms are another strategy to 
support HIV testing45–49 which could be based on elec-
tronic health records such as those in CPRD.
Although the results shown here are for a UK- based 
population the methodology may be applicable to other 
healthcare systems. They provide accurate testing rates 
and detection rates in primary care which are measures 
of HIV testing that can be used for international compar-
isons. A key element for preventing transmission and late 
diagnosis of HIV is testing in primary care, based on a 
screening strategy or indicator conditions.50 These data 
inform us of the current situation on testing and will 
be useful in planning and evaluating interventions to 
improve this.
The data on the discrepancy between PHE and CPRD 
prevalence of HIV positive status being recorded are 
another finding of importance for planning. New testing 
strategies such as home test and rapid testing outside 
of standard healthcare settings may contribute to the 
decrease in testing in primary care. These need to have 
a strategy in their delivery to feed back to primary care 
to maximise the benefits to patients and their health 
networks.
 COnClusIOns
HIV testing rates have declined in primary care in all age 
groups, although there has been a fall in late presenta-
tion. HIV testing rates are highest in London, and higher 
in urban areas than rural areas. Increased testing would 
likely increase the number of positive tests and help 
prevent late diagnosis. Further interventions to increase 
selectivity of testing (positive cases per test) may be 
required, either at the individual level using risk factors 
and HIV indicator conditions or at the practice level 
using knowledge of local HIV prevalence.
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